SlideShare a Scribd company logo
No
No
Yes
No
Black
JNC 8 Hypertension Guideline Algorithm
Lifestyle changes:
• Smoking Cessation
• Control blood glucose and lipids
• Diet
Eat healthy (i.e., DASH diet)
Moderate alcohol consumption
Reduce sodium intake to no
more than 2,400 mg/day
• Physical activity
Moderate-to-vigorous activity
3-4 days a week averaging 40
min per session.
Adult aged ≥ 18 years with HTN
Implement lifestyle modifications
Set BP goal, initiate BP-lowering medication based on algorithm
General Population
(no diabetes or CKD) Diabetes or CKD present
Age ≥ 60 years Age < 60 years All Ages
Diabetes present
No CKD
All Ages and Races
CKD present with or
without diabetes
BP Goal
< 150/90
BP Goal
< 140/90
BP Goal
< 140/90
BP Goal
< 140/90
Nonblack
Yes
Initiate thiazide or CCB,
alone or combo
Initiate ACEI or ARB,
alone or combo
w/another class
Reinforce lifestyle and adherence
Titrate medications to maximum doses or consider adding another medication (ACEI, ARB, CCB, Thiazide)
At blood pressure goal?
Reinforce lifestyle and adherence
Add a medication class not already selected (i.e. beta blocker, aldosterone antagonist, others) and titrate
above medications to max (see back of card)
Initiate thiazide, ACEI, ARB,
or CCB, alone or in combo
Reinforce lifestyle and adherence
Titrate meds to maximum doses, add another med and/or refer to hypertension specialist
Yes
Continue tx and monitoring
Initial Drugs of Choice for Hypertension
• ACE inhibitor (ACEI)
• Angiotensin receptor blocker (ARB)
• Thiazide diuretic
• Calcium channel blocker (CCB)
At blood pressure goal?
Strategy Description
A Start one drug, titrate to maximum
dose, and then add a second drug.
B Start one drug, then add a second
drug before achieving max dose of
first
C Begin 2 drugs at same time, as
separate pills or combination pill.
Initial combination therapy is
recommended if BP is greater than
20/10mm Hg above goal
At blood pressure goal?
Reference: James PA, Ortiz E, et al. 2014 evidence-based guideline for the management
of high blood pressure in adults: (JNC8). JAMA. 2014 Feb 5;311(5):507-20
Card developed by Cole Glenn, Pharm.D. & James L Taylor, Pharm.D.
Compelling Indications
Indication Treatment Choice
Heart Failure ACEI/ARB + BB + diuretic + spironolactone
Post –MI/Clinical CAD ACEI/ARB AND BB
CAD ACEI, BB, diuretic, CCB
Diabetes ACEI/ARB, CCB, diuretic
CKD ACEI/ARB
Recurrent stroke prevention ACEI, diuretic
Pregnancy labetolol (first line), nifedipine, methyldopa
Beta-1 Selective Beta-blockers – possibly safer in patients
with COPD, asthma, diabetes, and peripheral vascular
disease:
• metoprolol
• bisoprolol
• betaxolol
• acebutolol
Drug Class Agents of Choice Comments
Diuretics HCTZ 12.5-50mg, chlorthalidone 12.5-25mg, indapamide 1.25-2.5mg
triamterene 100mg
K+ sparing – spironolactone 25-50mg, amiloride 5-10mg, triamterene
100mg
furosemide 20-80mg twice daily, torsemide 10-40mg
Monitor for hypokalemia
Most SE are metabolic in nature
Most effective when combined w/ ACEI
Stronger clinical evidence w/chlorthalidone
Spironolactone - gynecomastia and hyperkalemia
Loop diuretics may be needed when GFR <40mL/min
ACEI/ARB ACEI: lisinopril, benazapril, fosinopril and quinapril 10-40mg, ramipril 5-
10mg, trandolapril 2-8mg
ARB: candesartan 8-32mg, valsartan 80-320mg, losartan 50-100mg,
olmesartan 20-40mg, telmisartan 20-80mg
SE: Cough (ACEI only), angioedema (more with ACEI),
hyperkalemia
Losartan lowers uric acid levels; candesartan may
prevent migraine headaches
Beta-Blockers metoprolol succinate 50-100mg and tartrate 50-100mg twice daily,
nebivolol 5-10mg, propranolol 40-120mg twice daily, carvedilol 6.25-25mg
twice daily, bisoprolol 5-10mg, labetalol 100-300mg twice daily,
Not first line agents – reserve for post-MI/CHF
Cause fatigue and decreased heart rate
Adversely affect glucose; mask hypoglycemic awareness
Calcium channel
blockers
Dihydropyridines: amlodipine 5-10mg, nifedipine ER 30-90mg,
Non-dihydropyridines: diltiazem ER 180-360 mg, verapamil 80-120mg 3
times daily or ER 240-480mg
Cause edema; dihydropyridines may be safely combined
w/ B-blocker
Non-dihydropyridines reduce heart rate and proteinuria
Vasodilators hydralazine 25-100mg twice daily, minoxidil 5-10mg
terazosin 1-5mg, doxazosin 1-4mg given at bedtime
Hydralazine and minoxidil may cause reflex tachycardia
and fluid retention – usually require diuretic + B-blocker
Alpha-blockers may cause orthostatic hypotension
Centrally-acting
Agents
clonidine 0.1-0.2mg twice daily, methyldopa 250-500mg twice daily
guanfacine 1-3mg
Clonidine available in weekly patch formulation for
resistant hypertension
Hypertension Treatment

More Related Content

What's hot

Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)
Hirdesh Chawla
 
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFSimultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Duke Heart
 
Choosing antiplatelet therapy before during and after hosp for acs
Choosing antiplatelet therapy before during and after hosp for acsChoosing antiplatelet therapy before during and after hosp for acs
Choosing antiplatelet therapy before during and after hosp for acs
cardiositeindia
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
ahvc0858
 
Newer anticoagulants
Newer anticoagulantsNewer anticoagulants
Newer anticoagulants
aravazhi
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
Dharmraj Singh
 
Adjusting drug dosing in ECMO patients
Adjusting drug dosing in ECMO patients Adjusting drug dosing in ECMO patients
Adjusting drug dosing in ECMO patients
Dr.Mahmoud Abbas
 
Ranolazine
RanolazineRanolazine
New day in heart failure
New day in heart failureNew day in heart failure
New day in heart failure
Waseem Omar
 
Paracetamol poisoning
Paracetamol poisoningParacetamol poisoning
Paracetamol poisoning
keerthi1805
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
Naser Tadvi
 
Role of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protectionRole of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protection
LPS Institute of Cardiology Kanpur UP India
 
NOAC Reversal Agents
NOAC Reversal AgentsNOAC Reversal Agents
NOAC Reversal Agents
Alexander Mok
 
PCSK9 Inhibitors PP
PCSK9 Inhibitors PPPCSK9 Inhibitors PP
PCSK9 Inhibitors PP
Vince Netto
 
Pcsk 9 inhibitors
Pcsk 9 inhibitorsPcsk 9 inhibitors
Calcium Channel Blockers
Calcium Channel BlockersCalcium Channel Blockers
Calcium Channel Blockers
guest9bc2b8
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icu
imran80
 
Bempedoic Acid.pptx
Bempedoic Acid.pptxBempedoic Acid.pptx
Bempedoic Acid.pptx
SubbuPoola1
 
Sacubitril valsartan EK
Sacubitril valsartan EKSacubitril valsartan EK
Sacubitril valsartan EK
Edgardo Kaplinsky
 
Atrial Fibrillation.pptx
Atrial Fibrillation.pptxAtrial Fibrillation.pptx
Atrial Fibrillation.pptx
ssuser2b7a9d
 

What's hot (20)

Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)
 
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFSimultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
 
Choosing antiplatelet therapy before during and after hosp for acs
Choosing antiplatelet therapy before during and after hosp for acsChoosing antiplatelet therapy before during and after hosp for acs
Choosing antiplatelet therapy before during and after hosp for acs
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
 
Newer anticoagulants
Newer anticoagulantsNewer anticoagulants
Newer anticoagulants
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
 
Adjusting drug dosing in ECMO patients
Adjusting drug dosing in ECMO patients Adjusting drug dosing in ECMO patients
Adjusting drug dosing in ECMO patients
 
Ranolazine
RanolazineRanolazine
Ranolazine
 
New day in heart failure
New day in heart failureNew day in heart failure
New day in heart failure
 
Paracetamol poisoning
Paracetamol poisoningParacetamol poisoning
Paracetamol poisoning
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Role of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protectionRole of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protection
 
NOAC Reversal Agents
NOAC Reversal AgentsNOAC Reversal Agents
NOAC Reversal Agents
 
PCSK9 Inhibitors PP
PCSK9 Inhibitors PPPCSK9 Inhibitors PP
PCSK9 Inhibitors PP
 
Pcsk 9 inhibitors
Pcsk 9 inhibitorsPcsk 9 inhibitors
Pcsk 9 inhibitors
 
Calcium Channel Blockers
Calcium Channel BlockersCalcium Channel Blockers
Calcium Channel Blockers
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icu
 
Bempedoic Acid.pptx
Bempedoic Acid.pptxBempedoic Acid.pptx
Bempedoic Acid.pptx
 
Sacubitril valsartan EK
Sacubitril valsartan EKSacubitril valsartan EK
Sacubitril valsartan EK
 
Atrial Fibrillation.pptx
Atrial Fibrillation.pptxAtrial Fibrillation.pptx
Atrial Fibrillation.pptx
 

Similar to 2014-JNC-8-Hypertension.pdf

Algoritma Terapi HT.docx
Algoritma Terapi HT.docxAlgoritma Terapi HT.docx
Algoritma Terapi HT.docx
ArviscoJatitamaRinan
 
Treatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptTreatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.ppt
marissaqurniati
 
HT guideline management97
HT guideline management97HT guideline management97
HT guideline management97
Munchukorn Leelatanon
 
Joint national committe 7
Joint national committe 7Joint national committe 7
Joint national committe 7
Noel Isaac
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of Hypertension
MedicineAndHealthCancer
 
ANTIHYPERTENSIVE THERAPY-market review 2013
ANTIHYPERTENSIVE THERAPY-market review 2013ANTIHYPERTENSIVE THERAPY-market review 2013
ANTIHYPERTENSIVE THERAPY-market review 2013
pooja sharma
 
Mellss yr4 primary care hypertension
Mellss yr4 primary care hypertensionMellss yr4 primary care hypertension
Mellss yr4 primary care hypertension
nur amalina aminuddin baki
 
Pharmacotherapy of hypertension
Pharmacotherapy of hypertensionPharmacotherapy of hypertension
Pharmacotherapy of hypertension
Dr Shahid Saache
 
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
thito6
 
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Vinh Pham Nguyen
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
Dr Karthik Balachandran
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special Situations
Rajat Biswas
 
Moins medical lecture.2(Antihypertensive Drugs 2).pdf
Moins medical lecture.2(Antihypertensive Drugs 2).pdfMoins medical lecture.2(Antihypertensive Drugs 2).pdf
Moins medical lecture.2(Antihypertensive Drugs 2).pdf
Moinul Islam
 
hypertension ppt on high bp By Dr kartik
hypertension ppt on high bp By Dr kartikhypertension ppt on high bp By Dr kartik
hypertension ppt on high bp By Dr kartik
KartikChoudhary496548
 
Hypertension KSU medical college
Hypertension KSU medical collegeHypertension KSU medical college
Hypertension KSU medical college
KhalafAlGhamdi
 
Anti htn medication.pptx maqsood
Anti htn medication.pptx maqsoodAnti htn medication.pptx maqsood
Anti htn medication.pptx maqsood
Mohd Maqsood
 
New Hypertension Guidelines
New Hypertension GuidelinesNew Hypertension Guidelines
New Hypertension Guidelines
magdy elmasry
 
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Dr Vivek Baliga
 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
DerekRuzzo
 
Hypertension 2014
Hypertension 2014Hypertension 2014
Hypertension 2014
Kyaw Win
 

Similar to 2014-JNC-8-Hypertension.pdf (20)

Algoritma Terapi HT.docx
Algoritma Terapi HT.docxAlgoritma Terapi HT.docx
Algoritma Terapi HT.docx
 
Treatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.pptTreatment of Hypertension YAKES.ppt
Treatment of Hypertension YAKES.ppt
 
HT guideline management97
HT guideline management97HT guideline management97
HT guideline management97
 
Joint national committe 7
Joint national committe 7Joint national committe 7
Joint national committe 7
 
Treatment of Hypertension Treatment of Hypertension
Treatment of Hypertension 	 Treatment of HypertensionTreatment of Hypertension 	 Treatment of Hypertension
Treatment of Hypertension Treatment of Hypertension
 
ANTIHYPERTENSIVE THERAPY-market review 2013
ANTIHYPERTENSIVE THERAPY-market review 2013ANTIHYPERTENSIVE THERAPY-market review 2013
ANTIHYPERTENSIVE THERAPY-market review 2013
 
Mellss yr4 primary care hypertension
Mellss yr4 primary care hypertensionMellss yr4 primary care hypertension
Mellss yr4 primary care hypertension
 
Pharmacotherapy of hypertension
Pharmacotherapy of hypertensionPharmacotherapy of hypertension
Pharmacotherapy of hypertension
 
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
Dt benh THA và chien luoc phoi hop thuoc nham dat muc tieu dt - Cn cac khuye...
 
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
Dieu tri-benh-tang-huyet-ap-va-chien-luoc-phoi-hop-thuoc-nham-dat-muc-tieu-di...
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
 
Hypertension; Basics- Recommendations - Special Situations
Hypertension; Basics-  Recommendations - Special SituationsHypertension; Basics-  Recommendations - Special Situations
Hypertension; Basics- Recommendations - Special Situations
 
Moins medical lecture.2(Antihypertensive Drugs 2).pdf
Moins medical lecture.2(Antihypertensive Drugs 2).pdfMoins medical lecture.2(Antihypertensive Drugs 2).pdf
Moins medical lecture.2(Antihypertensive Drugs 2).pdf
 
hypertension ppt on high bp By Dr kartik
hypertension ppt on high bp By Dr kartikhypertension ppt on high bp By Dr kartik
hypertension ppt on high bp By Dr kartik
 
Hypertension KSU medical college
Hypertension KSU medical collegeHypertension KSU medical college
Hypertension KSU medical college
 
Anti htn medication.pptx maqsood
Anti htn medication.pptx maqsoodAnti htn medication.pptx maqsood
Anti htn medication.pptx maqsood
 
New Hypertension Guidelines
New Hypertension GuidelinesNew Hypertension Guidelines
New Hypertension Guidelines
 
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationCombination Therapy In Hypertension - Dr Vivek Baliga Presentation
Combination Therapy In Hypertension - Dr Vivek Baliga Presentation
 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
 
Hypertension 2014
Hypertension 2014Hypertension 2014
Hypertension 2014
 

Recently uploaded

Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 

Recently uploaded (20)

Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 

2014-JNC-8-Hypertension.pdf

  • 1. No No Yes No Black JNC 8 Hypertension Guideline Algorithm Lifestyle changes: • Smoking Cessation • Control blood glucose and lipids • Diet Eat healthy (i.e., DASH diet) Moderate alcohol consumption Reduce sodium intake to no more than 2,400 mg/day • Physical activity Moderate-to-vigorous activity 3-4 days a week averaging 40 min per session. Adult aged ≥ 18 years with HTN Implement lifestyle modifications Set BP goal, initiate BP-lowering medication based on algorithm General Population (no diabetes or CKD) Diabetes or CKD present Age ≥ 60 years Age < 60 years All Ages Diabetes present No CKD All Ages and Races CKD present with or without diabetes BP Goal < 150/90 BP Goal < 140/90 BP Goal < 140/90 BP Goal < 140/90 Nonblack Yes Initiate thiazide or CCB, alone or combo Initiate ACEI or ARB, alone or combo w/another class Reinforce lifestyle and adherence Titrate medications to maximum doses or consider adding another medication (ACEI, ARB, CCB, Thiazide) At blood pressure goal? Reinforce lifestyle and adherence Add a medication class not already selected (i.e. beta blocker, aldosterone antagonist, others) and titrate above medications to max (see back of card) Initiate thiazide, ACEI, ARB, or CCB, alone or in combo Reinforce lifestyle and adherence Titrate meds to maximum doses, add another med and/or refer to hypertension specialist Yes Continue tx and monitoring Initial Drugs of Choice for Hypertension • ACE inhibitor (ACEI) • Angiotensin receptor blocker (ARB) • Thiazide diuretic • Calcium channel blocker (CCB) At blood pressure goal? Strategy Description A Start one drug, titrate to maximum dose, and then add a second drug. B Start one drug, then add a second drug before achieving max dose of first C Begin 2 drugs at same time, as separate pills or combination pill. Initial combination therapy is recommended if BP is greater than 20/10mm Hg above goal At blood pressure goal? Reference: James PA, Ortiz E, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: (JNC8). JAMA. 2014 Feb 5;311(5):507-20 Card developed by Cole Glenn, Pharm.D. & James L Taylor, Pharm.D.
  • 2. Compelling Indications Indication Treatment Choice Heart Failure ACEI/ARB + BB + diuretic + spironolactone Post –MI/Clinical CAD ACEI/ARB AND BB CAD ACEI, BB, diuretic, CCB Diabetes ACEI/ARB, CCB, diuretic CKD ACEI/ARB Recurrent stroke prevention ACEI, diuretic Pregnancy labetolol (first line), nifedipine, methyldopa Beta-1 Selective Beta-blockers – possibly safer in patients with COPD, asthma, diabetes, and peripheral vascular disease: • metoprolol • bisoprolol • betaxolol • acebutolol Drug Class Agents of Choice Comments Diuretics HCTZ 12.5-50mg, chlorthalidone 12.5-25mg, indapamide 1.25-2.5mg triamterene 100mg K+ sparing – spironolactone 25-50mg, amiloride 5-10mg, triamterene 100mg furosemide 20-80mg twice daily, torsemide 10-40mg Monitor for hypokalemia Most SE are metabolic in nature Most effective when combined w/ ACEI Stronger clinical evidence w/chlorthalidone Spironolactone - gynecomastia and hyperkalemia Loop diuretics may be needed when GFR <40mL/min ACEI/ARB ACEI: lisinopril, benazapril, fosinopril and quinapril 10-40mg, ramipril 5- 10mg, trandolapril 2-8mg ARB: candesartan 8-32mg, valsartan 80-320mg, losartan 50-100mg, olmesartan 20-40mg, telmisartan 20-80mg SE: Cough (ACEI only), angioedema (more with ACEI), hyperkalemia Losartan lowers uric acid levels; candesartan may prevent migraine headaches Beta-Blockers metoprolol succinate 50-100mg and tartrate 50-100mg twice daily, nebivolol 5-10mg, propranolol 40-120mg twice daily, carvedilol 6.25-25mg twice daily, bisoprolol 5-10mg, labetalol 100-300mg twice daily, Not first line agents – reserve for post-MI/CHF Cause fatigue and decreased heart rate Adversely affect glucose; mask hypoglycemic awareness Calcium channel blockers Dihydropyridines: amlodipine 5-10mg, nifedipine ER 30-90mg, Non-dihydropyridines: diltiazem ER 180-360 mg, verapamil 80-120mg 3 times daily or ER 240-480mg Cause edema; dihydropyridines may be safely combined w/ B-blocker Non-dihydropyridines reduce heart rate and proteinuria Vasodilators hydralazine 25-100mg twice daily, minoxidil 5-10mg terazosin 1-5mg, doxazosin 1-4mg given at bedtime Hydralazine and minoxidil may cause reflex tachycardia and fluid retention – usually require diuretic + B-blocker Alpha-blockers may cause orthostatic hypotension Centrally-acting Agents clonidine 0.1-0.2mg twice daily, methyldopa 250-500mg twice daily guanfacine 1-3mg Clonidine available in weekly patch formulation for resistant hypertension Hypertension Treatment